On Thursday, UBS initiated coverage on Iovance Biotherapeutics (NASDAQ:IOVA) stock with a Buy rating and a price target of $17.00. The firm expressed confidence in the company's commercial product, Amtagvi, and its potential success in the market, particularly for the treatment of second-line and beyond (2L+) melanoma.
The analyst from UBS anticipates that Amtagvi could achieve higher-than-expected revenues in fiscal year 2024, estimating $121 million, which surpasses the consensus of $114 million. The firm's outlook is based on the product's forecasted strong market launch and the operational capabilities of Iovance Biotherapeutics to facilitate product availability.
UBS highlighted that there do not appear to be any manufacturing bottlenecks that could impede the scale-up of Amtagvi in the near term. Additionally, the firm noted the significant patient demand at authorized treatment centers, which currently exceeds the supply of the product.
The analyst also pointed to the potential of Amtagvi in other areas, such as first-line melanoma and second-line and beyond non-small-cell lung cancer (NSCLC). These opportunities are seen as having asymmetric upside potential. UBS further mentioned that additional data expected in 2025 and 2026 could further de-risk Amtagvi's use in these indications, potentially unlocking more value for the company.
InvestingPro Insights
To complement UBS's positive outlook on Iovance Biotherapeutics (NASDAQ:IOVA), recent data from InvestingPro offers additional perspective on the company's financial position and market performance.
InvestingPro data shows that Iovance has a market capitalization of $2.98 billion, reflecting significant investor interest. The company's revenue for the last twelve months as of Q2 2024 stood at $32.77 million, with an impressive year-over-year revenue growth of 13,669.75%. This substantial growth aligns with UBS's optimistic revenue projections for Amtagvi.
Two relevant InvestingPro Tips highlight Iovance's financial strengths and challenges. Firstly, the company "holds more cash than debt on its balance sheet," indicating a strong liquidity position that could support the commercialization of Amtagvi. Secondly, analysts anticipate sales growth in the current year, which corroborates UBS's positive revenue forecast.
It's worth noting that InvestingPro offers 6 additional tips for Iovance Biotherapeutics, providing a more comprehensive analysis for investors interested in delving deeper into the company's prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.